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Available online 9 January 2016In acute inhalation toxicity studies, animals inhale substances at given concentrations. Without additional infor-
mation, however, appropriate starting concentrations for in-vivo inhalation studies are difﬁcult to estimate. The
goal of this project was the prevalidation of precision-cut lung slices (PCLS) as an ex-vivo alternative to reduce
the number of animals used in inhalation toxicity studies. According to internationally agreed principles for
Prevalidation Studies, the project was conducted in three independent laboratories. The German BfR provided
consultancy in validation principles and independent support with biostatistics.
In all laboratories, rat PCLS were prepared and exposed to 5 concentrations of 20 industrial chemicals under sub-
merged culture conditions for 1 h. After 23 h post-incubation, toxicity was assessed bymeasurement of released
lactate dehydrogenase and mitochondrial activity. In addition, protein content and pro-inﬂammatory cytokine
IL-1αweremeasured. For all endpoints IC50 values were calculated if feasible. For each endpoint test acceptance
criteria were established.
This report provides the ﬁnal results for all 20 chemicals. More than 900 concentration–response curveswere an-
alyzed. Log10[IC50 (μM)], obtained for all assay endpoints, showed best intra- and inter-laboratory consistency for
the data obtained byWST-1 and BCA assays.WhileWST-1 and LDH indicated toxic effects for themajority of sub-
stances, only some of the substances induced an increase in extracellular IL-1α. Two prediction models (two-
group classiﬁcation model, prediction of LC50 by IC50) were developed and showed promising results.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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For many substances, inhalation is the most relevant route of occupa-
tional exposure. Regulatory application of alternative methods to animal
testing, for both acute and repeated-dose inhalation toxicity studies, how-
ever, has lagged behind compared to other routes of administration, due
to the complexity of the respiratory system and the diversity of local
and systemic responses (Sullivan et al., 2014). It is further complicated
by the fact that for some substances, the lungs are themain route of expo-
sure but not the main target. Toxicity is then observed in other organs
such as the liver, spleen, and kidney (Hope and Hope, 2012; Kennedy,r Toxicology and Experimental
logy and In Vitro Toxicology,
. This is an open access article under2012; Vandebriel and De Jong, 2012). Nevertheless, the respiratory tract
is frequently themost sensitive and thusmost important target in inhala-
tion studies (Escher et al., 2010).
Alternative testmethods accepted by the regulatory authorities have
been published for in-vivo studies with topical and oral administration
of substances (BeruBe et al., 2009). For acute oral toxicity, for example,
several validated in-vivo alternatives are internationally accepted (e.g.
acute toxic class method, ﬁxed-dose procedure, up-and-down proce-
dure), optionally in combination with in-vitro testing of starting
concentrations (OECD TG423, 2001; OECD TG425, 2002; Guidance
Document, 2001; OECD, 2010). Similar approaches – merely based on
reﬁned and reduced animal testing – have been developed for acute in-
halation toxicity testing (acute toxic class method, TG436) (OECD
TG433, 2004; OECD TG436, 2009). There is, however, no validated in-
vitro alternative currently available for the respiratory system that is ac-
cepted by the regulatory authorities.
Inhalation of substances can induce various local and systemic ef-
fects such as respiratory irritation, acute and chronic inﬂammation,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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health outcomes include impaired respiratory function, severe organ in-
jury, hyperplasia, ﬁbrosis, and respiratory allergy (Hayes and Bakand,
2010). In view of this large diversity of effects, a single (non-animal test-
ing) alternative predicting the entire diversity of biological responses of
the respiratory tract is very unlikely to be found. On the other hand,
many in-vitro models resembling different parts of the respiratory
tract have been reported for scientiﬁc and industrial purposes
(Hansen et al., 2005; Hulette et al., 2002; Lalko et al., 2012; Larsson
et al., 2009; Megherbi et al., 2012; Mitjans et al., 2008; Nelissen et al.,
2009; Patlewicz et al., 2007; Python et al., 2009). Among them are single
cell lines forming monolayers, such as A549, BEAS-2B, and Calu-3, as
well as three-dimensional (3D) models of human-derived epithelium,
such as EpiAirway™ (MatTek Corporation, Ashland, MA, USA) and
MucilAir™ (Epithelix Sarl, Geneva, Switzerland) (Hirakata et al., 2010;
Huang et al., 2013; Ren and Daines, 2011; Reus et al., 2013). Moreover,
research has remarkably changed the general perception of organotypic
tissue models such as precision-cut lung slices (PCLS), parenchymal
strips, and isolated vessels and bronchi (Kroigaard et al., 2012;
Triﬁlieff et al., 2009). These models are considered to be of great impor-
tance, since themicroanatomy of the respiratory tract compriseswidely
varying cell types that may respond differently to the same substance
(Guilliams et al., 2013). Some in-vitro and ex-vivo models have been
established for prediction of organ injury, respiratory sensitization and
inﬂammation (Huang et al., 2009; Huang et al., 2011).
The goal of this BMBF-funded projectwas the scientiﬁc prevalidation
of rat PCLS (rPCLS) as an alternative test method for in-vivo dose range
ﬁnding experiments in acute inhalation toxicity studies. The projectwas
conducted in three independent laboratories (Fraunhofer ITEM, BASF
SE, and RWTH Aachen) according to internationally agreed principles
for Prevalidation Studies (Curren et al., 2006; OECDGD34, 2005) in con-
secutive phases over three years, aiming at a ﬁrst assessment whether
the rPCLS method is reliable and relevant for the intended purpose. To
achieve this, the study phases comprised (i) successful transfer of
methods from experienced to naïve laboratories, (ii) reﬁnement of
methods, (iii) development of robust test acceptance criteria, (iv) as-
sessment of reproducibility within and between laboratories, and
(v) proposal of a preliminary prediction model (PM) to allow predic-
tion of expected in-vivo toxicities from the in-vitro data (Archer
et al., 1997; Worth and Balls, 2001). To develop the PM, a training
set of twenty chemicals was used representing different chemistry
and different modes of toxicological action. The German FederalFig. 1.Theﬁgure in the top left corner shows themanagement of the study. Each laboratory subm
big ﬁgure shows the experimental design of inter-laboratory prevalidation of rat PCLS. Each par
independent biological runs. Twenty substances were tested. Each substance was applied at ﬁv
wasmeasured in duplicate (technical replicates). Cytotoxicitywasmeasuredby LDHandWST-1
assays. TC: tissue control with culturemedium only; VC: vehicle control, if necessary; CC: chemi
PC: positive control for WST-1 assay with AHCP; TPC: technical positive control for LDH assayInstitute for Risk Assessment (BfR) provided advice in conformity
with agreed validation principles and performed independent bio-
statistical analyses.
2. Materials and methods
2.1. Participants and organization
The three participating laboratories of the project were the Fraunho-
fer Institute for Toxicology and ExperimentalMedicine ITEM (Germany,
coordinating laboratory), BASF SE (Germany), and RWTH Aachen
(Germany). Coordinator of the project was A. Braun (Fraunhofer ITEM,
Germany). The German Federal Institute for Risk Assessment (BfR) pro-
vided support with biostatistics (Fig. 1). Teammeetings were organized
twice per year during the term of the project (2010–2013) in order to
share relevant information, develop details of the protocols, discuss re-
sults, and decide on the next steps. Practical training meetings for the
laboratory staff were performed to ensure correct use of the protocols.
Laboratory names were anonymized for this paper.
2.2. Media, reagents and chemicals
Dulbecco's Modiﬁed Eagle's Medium Nutrient Mixture F-12 Ham
(DMEM) with L-glutamine, 15 mM HEPES without phenol red,
pH 7.2–7.4, penicillin/streptomycin (P/S), low melting agarose,
Earle's Balanced Salt Solution (EBSS), triton X-100 (TX-100), ammo-
nium hexachloroplatinate (AHCP), lipopolysaccharide (LPS, from
Escherichia coli 0111:B4) and protease inhibitor cocktail were sup-
plied by Sigma Aldrich (Munich, Germany). Phosphate buffered sa-
line (PBS, without Ca2+ and Mg2+) was obtained from Lonza
(Wuppertal, Germany). Ammonium hexachloroplatinate, aniline,
ethanol, formaldehyde, n-hexyl chloroformate, methyl methacry-
late, paracetamol, paraquat, sodium dodecylsulfate, trimellitic anhy-
dride, triton-X 100, toluene diisocyanate, zinc oxide were purchased
from Sigma Aldrich (Munich, Germany). Isophorone diisocyanate
and octanoyl chloride were obtained from ABCR GmbH (Karlsruhe,
Germany). Acetic anhydride was supplied by Bernd Kraft GmbH
(Duisburg, Germany). Glutaraldehyde and lactose were purchased
from Fisher Scientiﬁc GmbH (Schwerte, Germany). Acetone and N,N-
dimethylformamide were obtained from Honeywell Riedel de Haёn
(Seelze, Germany). Enzyme-linked immunosorbent assay (ELISA) kits
were supplied by R&D Systems (DuoSets, Wiesbaden-Nordenstadt,itted its results to BfR for biostatistics. The studywas coordinated by Fraunhofer ITEM. The
ticipating laboratory performed identical experiments. Each substance was tested in three
e concentrations. Experiments included controls for every endpoint method. Each sample
assay. Extrinsic and intrinsic IL-1α andprotein contentwere determinedby ELISA and BCA
cal control of the highest tested concentrationwithout PCLS for chemical interference test;
with TX-100; EPC: positive control for ELISA with LPS; extr.: extrinsic; intr.: intrinsic.
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tion kit were purchased from Roche (Mannheim, Germany). BCA pro-
tein assay kit was obtained from Pierce (Rockford, IL, USA).
2.3. Laboratory equipment
Commonly used equipment was different in each laboratory. Major
equipment was as follows: laboratory A— Krumdieck tissue slicer (Ala-
bama Research & Development, USA), incubator (HeraCell, Thermo Sci-
entiﬁc Heraeus, Germany), ELISA Reader (MRX, Dynatech Laboratories,
USA); laboratory B — Krumdieck tissue slicer (Alabama Research and
Development, USA), incubator (BDD 6220, Thermo Scientiﬁc Heraeus,
Germany), Multilabel counter (Wallac 1420, Perkin Elmer, USA), ELISA
reader (Sunrise, Tecan, Switzerland); laboratory C — Krumdieck tissue
slicer (Alabama Research and Development, USA) or microtome
(#06.12.07, WissenschaftlicheWerkstatt, RWTH Aachen, Germany), in-
cubator (Innova CO-170, New Brunswick Scientiﬁc Co., Inc., USA),
GENios ELISA Reader (Tecan, Switzerland).
2.4. Animals
Female rats [Wistar, Crl:WI (Han) nulliparous and non-pregnant]
were housed under conventional and certiﬁed laboratory conditions in
a regular 12-hour dark/light cycle at ambient temperature of 22 ±
2 °C and a relative air humidity of 55 ± 15%. Diet and drinking water
were available ad libitum. Animals were acclimated for at least one
week and sacriﬁced at the age of 8–10 weeks.
2.5. Preparation of rat precision-cut lung slices (rPCLS)
Animals were sacriﬁced by an i.p. overdose (~100 mg/kg body
weight) of pentobarbital-Na and the lung was immediately dissected
without damaging the lung tissue. The trachea was cannulated and
the lung was ﬁlled with 10 mL/200 g body weight 37 °C-warm 1.5%
low-melting agarose medium solution, either before or after the lung
was separated from the animal. After polymerization of agarose to gel,
lung lobes were separated, and tissue cores (8 mm in diameter) were
prepared and cut into about 200–300 μm thick slices in 4 °C-cold EBSS
using a Krumdieck microtome (Alabama Research and Development,
Munford, AL, USA). Subsequently, tissue slices were incubated for 2 h
in DMEM, supplemented with 100 units/mL penicillin (P) andTable 1
Twenty test substances were selected for prevalidation of rPCLS. Substances were tested in rPCL
to known order in inhalation toxicity, chemical name, abbreviation, chemical class, CAS-numbe
viation; DMSO: dimethyl sulfoxide; EGDE: ethylene glycol dimethylether.
Substances Abbr. Class CAS #
Acetic anhydride Ac2O Anhydrides 108-24-7
Acetone Acetone Solvents 67-64-1
Ammonium
hexachloroplatinate
AHCP Metal compounds 16919-58-7
Aniline Aniline Amines 62-53-3
Ethanol Ethanol Solvents 64-17-5
Formaldehyde FA Solvents 50-00-0
Glutaraldehyde GA Aldehydes 111-30-8
Isophorone diisocyanate IPDI Isocyanates 4098-71-9
Lactose Lactose Carbohydrate 63-42-3
Methyl methacrylate MMA Acrylates 80-62-6
n-Hexyl chloroformate HCF Chloroformates 6092-54-2
N,N-dimethylformamide DMF Solvents 68-12-2
Octanoyl chloride OC Chlorides of organic acids 111-64-8
Paracetamol Paracetamol Analgetics 103-90-2
Paraquat Paraquat Pesticides 1910-42-5
Sodium dodecyl sulfate SDS Detergents 151-21-3
Trimellitic anhydride TMA Anhydrides 552-30-7
Triton X-100 TX-100 Detergents 9002-93-1
Toluene diisocyanate TDI Isocyanates 584-84-9 & 26471
Zinc oxide ZnO Metal compounds 1314-13-2100 μg/mL streptomycin (S) in a petri dish under standard cell culture
conditions (37 °C, 5% CO2). During this incubation period the medium
was exchanged every 30 min in order to remove cell debris.
2.6. Test substance selection
In this study, twenty chemicalswere chosen for determination of their
cytotoxic and pro-inﬂammatory potential using rPCLS: paraquat,
isophorone diisocyanate (IPDI), triton X-100 (TX-100), toluene
diisocyanate (TDI), AHCP, glutaraldehyde (GA), sodium dodecyl sulfate
(SDS), octanoyl chloride (OC), n-hexyl chloroformate (HCF), formalde-
hyde (FA), trimellitic anhydride (TMA), acetic anhydride (Ac2O),
aniline, zinc oxide (ZnO), N,N-dimethylformamide (DMF), methyl meth-
acrylate (MMA), ethanol, acetone, paracetamol, and lactose. Out of these
substances, lactose, which is well tolerated by inhalation and shows no
toxic effect in-vivo, and paracetamol, which is pharmacologically active
in liver, were proposed as negative controls. TX-100 was chosen as posi-
tive control substance. All other substances have knownmodes of toxico-
logical action via inhalation and can chemically be divided into acrylates,
aldehydes, amines, anhydrides, chloroformates, chlorides of organic acids,
isocyanates, solvents, and detergents. Two metal compounds were also
included. All investigated chemicals including CAS numbers, molecular
weights, and tested concentrations are listed in Table 1. All compounds
were purchased by one laboratory and distributed to the others. Supple-
ment Table 1 presents – as far as known – inhalation median lethal con-
centration (LC50) and oral median lethal dose (LD50) values and the
corresponding GHS classiﬁcation for all chemicals. No in-vivo experiment
had to be performed for the present study.
In some cases only in-vivo studies withmore or less than 4 h inhala-
tion were found. To classify these substances into GHS categories LC50
values were converted according to following formulas: LC50 value B
for A hours was converted into LC50 estimate value D for C hours using
for Gas/vapor: D = B√A / √C; and for Dust/mist: D = BA / C. In the
case of performing GHS classiﬁcation, enter 4 (hours) for C (GHS
Guidance, 2005).
Regarding acute inhalation toxicity and according to the Globally
Harmonized System (GHS), 15% of the substances (3/20) fall into cate-
gory 1 (LC50 ≤ 0.05 mg/L for aerosols, LC50 ≤ 0.5 mg/L for vapors, and
LC50 ≤ 100 ppm for gases), 25% (5/20) into category 2 (0.05 b
LC50 ≤ 0.5 mg/L for aerosols, 0.5 b LC50 ≤ 2.0 mg/L for vapors, and
100 b LC50 ≤ 500 ppm for gases), 15% (3/20) into category 3S in all three participating laboratories. Table shows for each substance: number according
r, molecular weight, used vehicle, tested concentrations, and dilution factor. Abbr.: abbre-
M
[g/mol]
Vehicle Tested concentrations
[mM]
Dilution
factor
Purity
102.1 – 2.3, 5.0, 10.8, 23.3, 50.0 2.15 ≥99.5%
58.1 – 458, 732, 1172, 1875, 3000 1.6 ≥99.9%
443.9 – 0.05, 0.1, 0.2, 0.5, 1.0 2.15 ≥99.9%
93.1 – 4.7, 10.1, 21.6, 46.5, 100.0 2.15 ≥99.5%
46.1 – 534, 854, 1367, 2188, 3500 1.6 ≥99.8%
30.3 – 0.8, 2.0, 5.0, 12.4, 31.0 2.5 37 wt.%
100.1 – 0.2, 0.5, 1.1, 2.3, 5.0 2.15 25 wt.%
222.2 0.5% DMSO 0.1, 0.3, 0.5, 1.2, 2.5 2.15 ≥97.5%
342.3 – 4.7, 10.1, 21.6, 46.5, 100.0 2.15 ≥99.0%
100.1 – 4.7, 10.1, 21.6, 46.5, 100.0 2.15 ≥98.5%
164.6 0.5% DMSO 4.7, 10.1, 21.6, 46.5, 100.0 2.15 ≥96.5%
73.1 – 381, 610, 977, 1563, 2500 1.6 ≥99.9%
162.7 1% ethanol 4.6, 7.3, 11.7, 18.8, 30.0 1.6 ≥98.5%
151.2 – 4.2, 9.1, 19.5, 41.9, 90.0 2.15
257.2 – 0.4, 1.3, 4.0, 12.7, 40.0 3.16 ≥97.5%
288.4 – 0.05, 0.1, 0.2, 0.5, 1.0 2.15 ≥99.0%
192.1 0.5% DMSO 3.1, 4.9, 7.9, 12.5, 20.0 1.6 97%
647.0 – 0.02, 0.05, 0.11, 0.23, 0.50 2.15 ≥99.0%
-62-5 174.2 1% EGDE 4.7, 10.1, 21.6, 46.5, 100.0 2.15 ≥94.5%
81.4 0.1% acetic acid 0.1, 0.3, 0.5, 1.2, 2.5 2.15 ≥99.0%
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500 b LC50 ≤ 2500 ppm for gases), 15% (3/20) into category 4
(1.0 b LC50 ≤ 5.0 mg/L for aerosols, 10.0 b LC50 ≤ 20.0 mg/L for vapors,
and 2500 b LC50 ≤ 20,000 ppm for gases), and 30% (6/20) into category
5. The criteria for category 5 are intended to enable identiﬁcation of sub-
stances which are of relatively low acute toxicity hazard, but under cer-
tain circumstances may present a danger to vulnerable populations.
These substances are anticipated to have an oral or dermal LD50 in the
range of 2000–5000 mg/kg body weight and equivalent doses for
inhalation.
2.7. Exposure of rPCLS to substances
Twenty substances were tested in all participating laboratories, each
in three independent experiments minimum (biological replicates,
N ≥ 3). Endpoints were evaluation of membrane integrity via LDH
assay, mitochondrial activity via WST-1 assay, protein content via BCA
assay, and intrinsic and extrinsic IL-1α content via ELISA.
Substances were treated as “unknown” and tested according to the
following procedure: (i) checking of solubility and dilution steps, and
if necessary (ii) ﬁnding of appropriate solvents for heavily soluble or in-
soluble chemicals without additional effects of the solvent on tissue.
Thus, substances were dissolved in DMEM+ P/S, if necessary with an
appropriate vehicle, in ﬁve different concentrations using dilution fac-
tors as given in Table 1. Then 24-well cell culture plates were ﬁlled
with 500 μL of pre-warmed substance solution per required well. Two
visually round and intact rPCLS per well were added. Four replicates
were used for each substance concentration: two technical replicates
for LDH andWST-1 assay and two technical replicates for measurement
of protein and IL-1α content. The experimental design is presented in
Fig. 1. After 1 h of exposure under standard cell culture conditions, a
three-fold washing step was performed to remove the substances
from the tissue (except for the technical positive control, see below),
followed by a post-incubation period of 23 h with DMEM+ P/S. Differ-
ent exposure time periods have been compared before start of the
study, including pulse exposure vs. permanent exposure. Finally, the
combination of 1 h pulse exposure plus 23 post-incubation was select-
ed. For this approach we obtained optimal effects on cytotoxicity
using WST-1 and LDH assay without e.g. loss of LDH activity due to in-
terferences with substances. Plates were sealed with an adhesive ﬁlm
to account for volatility of substances for the entire incubation time.
In parallel with the chemically treated tissue samples, a tissue con-
trol (TC) cultivated only with culture medium, a chemical control (CC)
without rPCLS (substance interference test for WST-1 and LDH assays),
a positive control (PC) for WST-1 assay with 200 μMor 500 μMAHCP, a
technical positive control (TPC) for LDH assay with 0.1% TX-100, a pos-
itive control for ELISA (EPC)with 100 ng/mL LPS and, when necessary, a
vehicle control (VC) were prepared. VC tissue slices were treated with
the vehicle selected for the test item using the same concentration as
in the tissue slices exposed to the test item.
2.8. Cytotoxicity assays
Cytotoxicity of substances was determined using the cell prolifera-
tion kit WST-1 and LDH cytotoxicity detection kit. For the WST-1
assay the medium was removed from the rPCLS and 250 μL of the
WST-1 working reagent per well were added. After 1 h of incubation
under standard cell culture conditions, 100 μL of supernatant were
transferred to a 96-well plate in duplicates. Absorbance was measured
at 450 nmwith a reference wavelength of 600–700 nm.
For the LDH assay 50 μL of tissue culture supernatant were trans-
ferred to a 96-well plate in duplicates. Fifty μL of LDH reaction mixture
were added and plates were incubated for 20min at room temperature,
protected from light. Absorbancewasmeasured at 490 nmwith a refer-
ence wavelength of 690 nm.2.9. Protein determination
The BCA assay is based on the colorimetric detection of a
bicinchoninic acid/Cu+ complex which is inﬂuenced by the presence
of protein bonds. It is widely used for the determination of protein
concentrations.
At the end of culture period, supernatant was removed and the total
protein content of the remaining tissue was subsequently measured
using the BCA assay. The tissue was therefore lysed by incubation with
500 μL 1% TX-100 in PBS, pH 7.4 plus 0.2% protease inhibitor cocktail
at standard cell culture conditions for 1 h. The extracted total protein
of the tissuewasmeasured by using the protocol of the Pierce® BCA pro-
tein assay kit. Bovine serum albumin (included in the assay kit) was
used for the standard curve.
2.10. ELISA: quantiﬁcation of IL-1α
Culture supernatant was removed at the end of culture period. The
remaining tissue was lysed by incubation with 500 μL 1% TX-100 in
PBS, pH 7.4 plus 0.2% protease inhibitor cocktail at standard cell culture
conditions for 1 h. IL-1α was measured in supernatants and lysis ex-
tracts of rPCLS using commercially available ELISA kits according to
the manufacturer's protocol. For the eight-point standard curve recom-
binant rat IL-1α, included in the kit, was used. The lower and upper
limits of quantiﬁcation were at 16 pg/mL and 1000 pg/mL, respectively.
2.11. Deﬁnition of acceptance criteria
At the beginning of the project initial protocols based on existing
protocols and experience were used. According to Prevalidation princi-
ples, during the pilot phase six substances shown in Table 1 (aniline, GA,
lactose, MMA, paracetamol, TX-100) were used to reﬁne the rPCLS pro-
tocols and to develop robust test acceptance criteria (ACs) for each end-
point based on data from three different laboratories. Both, the ﬁnal
rPCLS endpoint protocols and the biostatistically developed ACs for
each endpoint protocol were then included in ﬁnal standard operating
procedures (SOPs) and later applied to the remaining 14 test chemicals.
The next section gives a detailed description of the ACs established for
each of the individual endpoints in order to assure reliable and valid
assay performance in each laboratory. Only if each acceptance criterion
for each individual endpointwasmet the datawere accepted for further
evaluation and curve ﬁtting. An experiment had to be repeated, if one of
the endpoint-speciﬁc controls did not meet the established acceptance
criteria.
Depending on the toxicological endpointmeasured three to four dif-
ferent ACs per endpoint assay were deﬁned (Table 2). In general, the
ACs for all endpoint assays were established to ensure aminimum tech-
nical quality, to deﬁne endpoint related values for the negative and pos-
itive reference samples and – for the BCA and IL-1α assay – to ensure a
minimum quality of the standard curves.
In detail, AC1, controlling the magnitude of technical errors, was
generally used for all endpoints (except IL-1α) and was set to ≤0.3.
For the cytotoxicity assays ACs were deﬁned so as to assure sufﬁciently
high tissue viability of non-substance-exposed reference samples. For
the WST-1 assay this was achieved by deﬁning of a minimum optical
density of TC and VC equal to or greater than 0.6 (WST-1 AC2). For the
LDH assay AC2 assured cellular tissue integrity under untreated condi-
tions, thus release of LDH in TC and VC had to be ≤30% in comparison
with the TPC (LDH AC3). Further ACs (WST-1 AC3; LDH AC2) demon-
strated responsiveness of the tissue to an active substance. Therefore,
AHCP was used in laboratory-speciﬁc concentrations for the WST-1
assay. This PC had to reduce viability to 66% minimum in comparison
with the TC. To demonstrate a maximum response of rPCLS in the LDH
assay, TX-100 was used as TPC (Table 2). Here, TPC had to have a mini-
mum optical density of 1.0. The standard curve of BCAwas evaluated by
analysis of eight calibration standards using a three-parameter logistic
Table 2
Endpoint speciﬁc acceptance criteria. AC: acceptance criteria; OD: optical density; TC: tis-
sue control only with culture medium; VC: vehicle control; PC: positive control forWST-1
assay with AHCP; TPC: technical positive control for LDH assaywith TX-100; EPC: positive
control for ELISA with LPS; BSA: bovine serum albumin; Sy,x: residual standard error;
CVadj: offset adjusted coefﬁcient of variation.
Assay Acceptance
criteria
Deﬁnition
WST-1 AC1 Difference between duplicate ODmeasurements has to be ≤0.3
AC2 Minimum OD of the TC and VC has to be ≥0.6
AC3 PC has to be ≤66% of the TC and VC
LDH AC1 Difference between duplicate ODmeasurements has to be ≤0.3
AC2 Minimum OD of the TPC has to be 1.0
AC3 TC and VC have to be ≤30% of the TPC
BCA AC1 Difference between duplicate ODmeasurements has to be ≤0.3
AC2 Mean OD of the maximum BSA concentration of standard
curve has to be ≥0.8
AC3 Sy,x of the ﬁt of the standard curve has to be ≤0.1
AC4 Mean OD of the TC and VC has to be ≥0.3
IL-1α AC1 Restricting CVadj has to be ≤20%
AC2 Mean OD of the maximum concentration of standard curve
has to be ≥1.0
AC3 Sy,x of the ﬁt of the standard curve has to be ≤0.1
AC4 EPC has to be ≥140% of the TC and VC for intrin. IL-1α
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higher than 0.8, which provides a standard curve covering a sufﬁciently
high dynamic range (BCA AC2). The quality of standard curve ﬁt was
controlled by the residual standard error (Sy,x), which had to be equal
to or lower than 0.1 (BCAAC3). The total protein content of two untreat-
ed tissue sections (TC and VC) was deﬁned at a minimum optical
density of 0.3 (BCA AC4). Similar quality control checks were used for
IL-1α (Table 2). AC4 here was used to assure a sufﬁciently high anti-
inﬂammatory cytokine response of tissue exposed to LPS. It had to result
in 140% ormore intrinsic IL-1α for the TC or VC. All ACs are summarized
in Table 2.
2.12. Data management
All laboratories used the same EXCEL spreadsheet template, devel-
oped by BfR and Fraunhofer ITEM, to capture all test results. The struc-
ture and functions of this template were write-protected. To allow ad
hoc decisions about the test validity at the laboratory level, the results
for all acceptance criteria were calculated by the implemented func-
tions. All data entered were submitted to the project partner BfR re-
sponsible for further analysis across laboratories. Curve ﬁtting and
statistical analyses were performed as described below.
2.13. Curve ﬁtting
For all endpoints a sigmoid concentration–response model was ﬁtted
to the data and IC50 values were calculated. Curve ﬁtting and analysis
were performed automatically using the statistical computing environ-
ment R (R Development Core Team, 2010). The functions “loess” for
non-parametric ﬁtting, “drm” (Ritz, 2005) for parametric ﬁtting, and
“mrdrm” for a combination of the two were employed. For curve ﬁtting
amodel-robust approachwas used (NottinghamandBirch, 2000). The re-
sponse (y) is predicted by aweighted sum of a parametric ﬁtting (y^p) and
a non-parametric ﬁtting (y^np):
y^ ¼ 1−λð Þy^p þ λy^np:
The non-parametric ﬁtting applied was a local linear regression
procedure. The mixing parameter λ is determined in the generalized
cross-validation procedure PRESS (Nottingham and Birch, 2000). For
the endpoints WST-1, BCA, and intrinsic IL-1α a parametric model
was used, either a three-parametric log-logistic model or theBrain–Cousens model (Ritz, 2005). The Brain–Cousens model is
given by the following equation:
y xð Þ ¼ d− fx
1þ exp b log xð Þ− log eð Þð Þð Þ ;
where x denotes the dose and y(x) the response, the shape of which
is determined by the parameters b, d, f and e.
Akaike's information criterion (AIC) (Akaike, 1998) was calculated
for each ﬁtting of a data set according to both models. This approach
adds to the logarithm of the residual sum of squares the number of pa-
rameters used, thus penalizing smaller residual sum of squares with the
number of parameters. The model yielding the smaller AIC was chosen
as parametric part of the approach. For the endpoints LDH and extrinsic
IL-1α a four-parametric log-logistic model was chosen (Ritz, 2005). The
non-parametric ﬁtting was performed by local linear regression
(Nottingham and Birch, 2000).
2.14. Calculation of laboratory-speciﬁc and overall mean and median IC50
and log IC50
For WST-1, BCA, and IL-1α assay the IC50 value refers to the concen-
tration, at which curve ﬁtting as described above predicts half the value
of the corresponding non-exposed control. For LDH assay the IC50 was
deﬁned as concentration,which predicts the average of the correspond-
ing non-exposed control and the mean value of the TPC. To determine
this point a bisection procedure was applied using the R function bisect
from the package pracma, which ﬁnds roots of univariate functions in
bounded intervals (Borchers, 2015). The search for IC50 was performed
in an interval from 0 to 5 times the maximum concentration applied.
IC50 values were ﬁrst calculated endpoint-speciﬁcally for each
substance and laboratory. Majority rules were applied in this process
for the three independent runs of a single laboratory. Laboratory-
independent overall IC50 values were calculated as mean or median of
the individual laboratory-speciﬁc IC50 values.
Median log IC50 values of each substance for each endpoint and lab-
oratory were used for regression and classiﬁcation of the substances.
Themedianwas employed, because it is a robust estimate of the central
tendency, which minimizes potential biases originating from outliers.
Additionally, in contrast to the mean the median can be calculated,
even if for some curves only minimal (N) IC50 values have been estimat-
ed. In case only minimal IC50 values could be estimated for the majority
of replicates, i.e. the only information obtained was that the IC50 was
greater than a certain value, this value was used for further analysis.
2.15. Analysis of intra- and inter-laboratory variances
The standard deviation (Stdev) and coefﬁcient of variation (Cv =
Stdev / mean ∗ 100%) of the logarithmically (decimal) transformed
IC50 values, denoted as log-transformed (log IC50), were used asmeasures
of dispersion to describe variability of IC50. This provides a ﬁrst estimation
of the variance per endpoint and substance within (intra-laboratory var-
iance) and across (inter-laboratory variance) laboratories.
2.16. Two-group classiﬁcation model
In the two-group classiﬁcation model, substances were divided into
two classes based on their in-vivo acute inhalation toxicity (toxic and
non-toxic). Substances with GHS categories 1, 2, and 3 were assigned
to the toxic class and substances with GHS categories 4 and 5 to the
non-toxic class. To classify the results of the present study the median
of log IC50 values from theWST-1 assay was calculated for each labora-
tory and each substance. The in-vitro class center of the toxic class was
then calculated as of the median for all substances that had been
assigned to this class in-vivo. The same was done for the non-toxic
class. Finally, the mean of these two medians was deﬁned as the
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below this threshold was classiﬁed as “toxic”, whereas substances
with median values above the threshold were classiﬁed as “non-toxic”.
2.17. Prediction of the LC50 by IC50
The in-vivo lethality values of the substances used in this project
were used to develop a prediction model (see also Supplement
Table 1). For some chemicals only inhalation LC50 values from studies
with exposure durations different from 4 h were found. In these cases,
the LC50 values were converted to 4-h LC50 values.
In order to develop a prediction model, which allows for estimation
of LC50 by IC50 a linear regression analysis was performed with values
from laboratory C. The log IC50 values of WST-1 assay were regarded
as predictors and the log-transformed LC50 values were regarded as re-
sponse:
log10 LC50ð Þ ¼ β0 þ β1 log10 IC50ð Þ:
2.18. Sensitivity and speciﬁcity
Sensitivity and speciﬁcity provide measures for the ability of an assay
to correctly identify positive and negative results (in the present study to
correctly classify substances as toxic or non-toxic). The sensitivitywas cal-
culated as the number of correct positives (correctly identiﬁed as toxic) /
(number of correct positives + number of false negatives (incorrectly
identiﬁed as non-toxic)). Speciﬁcity was calculated as the number of cor-
rect negatives (correctly identiﬁed as non-toxic) / (number of correct
negatives + number of false positives (incorrectly identiﬁed as toxic)).
2.19. Statistics
Statistical analysis was performed by using the one-way ANOVA
(software: GraphPad Prism 4, version 4.03). The outcomes of the post-
hoc treatment to control comparisons with Bonferroni adjustment of
p-values to account for multiple testing are reported. Differences be-
tween treated samples and controls were considered statistically signif-
icant at the level of p b 0.05. Comparison of data was analyzed as
indicated in the appropriate section using either parametric correlation
(Pearson's product moment correlation and two-tailed P value) or non-
parametric correlation (Spearman's rank correlation r).
3. Results
3.1. Acceptance criteria
Absorbance values represented the raw data in the different end-
point assays. Consequently, most of AC referred to the optical density
of the samples (Table 2). Deviations from any of the acceptance criteria
indicated a problem likely related to assay quality or experimental con-
duct. In the cytotoxicity assays, quality controls indicatedwhen viability
of the tissue was insufﬁciently low. Responsiveness of the tissue to an
effective toxic substancewas included as positive control. Based on con-
centration–response curves, minimumandmaximum values of absorp-
tion were deﬁned and had to be met for subsequent experiments.
Further ACs were used to control the quality of standard curves as
generated in the BCA and ELISA assays. These ACs (AC2 and AC3) guar-
anteed sufﬁcient spreading of absorption values, providing a high dy-
namic range as well as a close ﬁtting between predicted and observed
responses of standard curves. An important issue was the deﬁnition of
a minimum absorption value for non-treated tissue sections (tissue
and vehicle controls). Instead ofmeasuring and standardizing the thick-
ness of slices, measurement of total protein content was used to indi-
rectly monitor thickness of lung slices.To ensure that the requirements (Table 2) were fulﬁlled, all samples
were entered for evaluation, automatically checked and accepted for
further analysis only if the deﬁned criteria were met. Supplement
Table 2 gives the number of samples entered for evaluation and the pro-
portion [%] of ﬁnally accepted cases for the lastly tested substances
(DMF, ethanol, acetone, formaldehyde). AC1, which represents the
magnitude of technical errors such as pipetting errors for every assay,
was met in ≥95% of all experiments. In the WST-1 and LDH assays AC2
and AC3 were also met in most cases (≥83%). For BCA assay the quality
requirement for the standard curves (AC2 and AC3) was fulﬁlled in all
experiments in all laboratories. The minimum optical density of un-
treated samples (AC4) of the BCA assay was also reached in all experi-
ments. Fulﬁllment of AC2 and AC3 as quality criteria for the ELISA
standard curves ranged from 92% to 100%. Experiments that did not
meet all endpoint-speciﬁc AC were not used for calculation of the IC50
and correlation with in-vivo. These experiments were repeated and
the data used for subsequent determinations of IC50 values. In general,
fulﬁllment of test acceptance criteria improved over the entire project
time.
3.2. Substance-induced cytotoxicity in rPCLS: log IC50 results for all
endpoints
In each participating laboratory rPCLSwere prepared and exposed to
ﬁve concentrations of 20 preselected substances (Table 1). This paper
reports the ﬁnal results for all substances. Concentration–response
curve data from the various qualiﬁed assays were used for non-linear
sigmoidal curve ﬁtting using mathematical models. Logarithmically
transformed IC50 [μM] values (log IC50) were calculated for each sub-
stance, laboratory, and endpoint (Supplement Tables 3 to 6). More
than 900 curves have been ﬁtted. Datameeting acceptance automatical-
ly were used to determine overall mean and median log IC50 values for
each endpoint and most of the substances (Table 3).
For 18 of 20 substances deﬁned median log IC50 values could be cal-
culated forWST-1 assay for all laboratories (Supplement Table 3, Fig. 2A,
Table 3). ForMMAand lactose, onlyminimal (N) IC50 valueswere exam-
ined except for laboratory C.Median log IC50 values constantly covered a
wide range of approximately four orders ofmagnitude from1.91 (corre-
sponding IC50 value: 81 μM) for TX-100 to 6.17 (corresponding IC50
value: 1.45 M) for ethanol. The majority of log IC50 values calculated
by each laboratory was within the measured concentration range,
with few exceptionswhere IC50 valueswere found to be above themax-
imum applied concentrations (IPDI, TMA, TDI, paracetamol, see Supple-
ment Table 3). In three cases outliers were detected with a Grubbs test
(Grubbs, 1950) (laboratory C: SDS, OC, acetone). For the calculation of
themedian the outliers were not excluded. For a single laboratory a de-
ﬁned log IC50 for lactose could only be obtained by extrapolation.
The second cytotoxicity assay used was the LDH assay. It ﬁnally
yielded a less complete data set than the WST-1 assay. Concentration–
response curves provided deﬁned log IC50 values for only 11 out of 20
substances in all laboratories (Supplement Table 4, Fig. 2B, Table 3). Of
those 11 deﬁned IC50 values three could only be determined in one lab-
oratory and two additional values in only two laboratories. Median log
IC50 values covered approximately four orders of magnitude from 2.46
for SDS (corresponding IC50 value: 288 μM) to 6.52 for acetone (corre-
sponding IC50 value: 3.3 M). After lactose and MMA exposure no effect
was observed on LDH release. The reason why many substances failed
to be ﬁtted must be a matter of some considerable concern and needs
explanation. Please refer to the discussion chapter.
Total protein contentwas quantiﬁed using BCA assay. Log IC50 values
could also be calculated for 20 substances (Supplement Table 5, Fig. 2C,
Table 3). Median log IC50 values ranged from 2.25 for TX-100 (corre-
sponding IC50 value: 178 μM) to 6.59 for acetone (corresponding IC50
value: 3.9 M) (Table 3). MMA treatment in most cases had no effect
on the total protein content of lung slices. IPDI and lactose treatment
provided deﬁned values in one laboratory.
Table 3
Mean and median of endpoint speciﬁc log-transformed IC50 [log IC50 (μM)] for all tested
chemicals ± inter-laboratory standard deviation (Stdev) and coefﬁcient of variation
(Cv). Log IC50 values are given for A) WST-1 assay, B) LDH assay, C) BCA assay, and
D) intrinsic IL-1α (intIL-1α) as measured by ELISA. Chemicals are ranked by increasing
median log IC50 values. The number of each substance refers to known order in inhalation
toxicity (see also Table 1). Abbreviations of chemicals are given according to Table 1. “N”
values are described in the Materials and methods section.
Chemical Median log IC50 Mean log IC50 Inter-lab. Stdev Inter-lab. Cv
A WST-1 assay
3 TX-100 1.91 1.89 0.05 2
7 SDS 2.42 2.39 0.06 2
5 AHCP 2.61 2.60 0.03 1
14 ZnO 2.86 2.99 0.12 4
6 GA 3.14 3.10 0.17 5
2 IPDI 3.16 3.25 0.21 7
1 Paraquat 3.53 3.34 0.15 4
10 FA 3.67 3.70 0.12 3
11 TMA 4.00 4.16 0.43 11
8 OC 4.18 4.19 0.04 1
12 Ac2O 4.19 4.19 0.04 1
9 HCF 4.32 4.23 0.26 6
13 Aniline 4.77 4.61 0.31 6
4 TDI 4.83 4.84 0.27 6
20 Paracetamol 4.94 4.92 0.20 4
16 MMA N5.70 N5.70 NA NA
19 Lactose N5.70 5.56 0.07 1
18 Acetone 6.11 6.16 0.19 3
15 DMF 6.14 6.11 0.11 2
17 Ethanol 6.17 6.18 0.04 1
B LDH assay
7 SDS 2.46 2.46 – –
5 AHCP 2.94 2.90 0.10 3
14 ZnO 2.99 3.09 0.32 11
2 IPDI 3.64 3.71 – –
6 GA 3.71 3.71 – –
1 Paraquat 4.24 4.20 0.45 11
10 FA 4.38 4.31 0.04 1
13 Aniline 4.94 5.01 0.06 1
20 Paracetamol 5.15 5.12 0.03 1
15 DMF 6.29 6.29 0.48 8
18 Acetone 6.52 6.52 0.08 1
C BCA assay
3 TX-100 2.25 2.24 0.04 2
7 SDS 2.63 2.63 0.08 2
5 AHCP 3.13 3.17 0.09 3
14 ZnO 3.46 3.42 0.33 9
6 GA 3.68 3.76 0.28 8
11 TMA 4.06 4.06 0.54 13
2 IPDI 4.10 2.93 0.68 16
8 OC 4.24 4.26 0.01 0
12 Ac2O 4.29 4.33 0.05 1
10 FA 4.50 4.58 0.19 4
9 HCF 4.64 4.65 0.03 1
1 Paraquat 4.84 4.80 0.31 6
13 Aniline 4.93 4.85 0.10 2
4 TDI 4.98 4.88 0.49 10
20 Paracetamol 5.28 5.25 0.25 5
19 Lactose 5.70 5.59 0.06 1
16 MMA N5.70 N5.70 0.00 0
15 DMF 6.37 6.35 0.07 1
17 Ethanol 6.43 6.52 0.01 0
18 Acetone 6.59 6.45 0.44 7
D intIL-1α ELISA
3 TX-100 2.21 2.17 0.13 6
7 SDS 2.40 2.21 0.57 24
5 AHCP 2.83 2.83 0.23 8
14 ZnO 3.08 3.02 0.09 3
6 GA 3.23 3.21 0.18 6
2 IPDI 4.10 3.40 0.20 6
10 FA 3.59 3.67 0.20 5
11 TMA 4.03 4.00 0.58 14
9 HCF 4.17 4.10 0.44 11
8 OC 4.23 4.21 0.10 2
12 Ac2O 4.29 4.23 0.12 3
1 Paraquat 4.58 4.72 0.24 5
Table 3 (continued)
Chemical Median log IC50 Mean log IC50 Inter-lab. Stdev Inter-lab. Cv
D
13 Aniline 4.75 4.46 0.64 13
4 TDI 4.8 4.49 0.58 12
20 Paracetamol 4.84 4.88 0.29 5
16 MMA 5.42 5.09 0.49 9
19 Lactose 5.70 5.20 0.29 5
15 DMF 6.13 6.14 0.04 1
17 Ethanol 6.27 6.24 0.06 1
18 Acetone 6.30 6.20 0.57 9
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IL-1α as a biomarker of inﬂammation was assessed using ELISA. In-
tracellular IL-1αwas either unchanged or decreased to levels below tis-
sue control (Table 3D). Only paraquat very signiﬁcantly increased
intracellular IL-1α levels of up to 140% vs. controls (laboratory A). As
intracellular IL-1α decreased with increasing cytotoxicity, it was used
to determine mean and median log IC50 values (Supplement Table 6,
Fig. 2D, Table 3D). Median values hardly covered 5 orders of magnitude
from 2.21 for TX-100 (corresponding IC50 value: 162 μM) to 6.30 for ac-
etone (corresponding IC50 value: 2.0 M). Extracellular IL-1α was very
low in control tissue. Even if tissue was stimulated with LPS, which is
an activator of the innate immune system, most of the induced IL-1α
could only be detected intracellularly after 24 h. Nevertheless, the re-
sults showed extracellular IL-1α to be increased signiﬁcantly after expo-
sure to Ac2O, AHCP, aniline, ethanol, FA, GA, paracetamol, paraquat,
SDS, TMA, and TX-100 in at least one laboratory. No increase or decrease
could be observed after exposure with lactose, MMA, HCF, and TDI.
Other chemicals induced a non-signiﬁcant increase of extracellular IL-
1α in at least two laboratories (Fig. 3). The increases were observed in
the herein reported three independent experiments.3.4. Intra- and inter-laboratory variability
Experiments were performed under as near identical conditions as
possible. Beside all steps that were performed to minimize variability
and are already described in the Materials and methods (e.g. material,
equipment, SOPs), the staff was intensively trained — on site if neces-
sary. We performed no staff swapping and blind evaluations but all
data were submitted to and evaluated by an independent partner.
Intra-laboratory variability of log IC50 was evaluated for each of the
biological replicates (N= 3) for each substance and laboratory. Results
of the three laboratories were used to determine inter-laboratory vari-
ances. Mean values, standard deviation (Stdev), and coefﬁcient of vari-
ation (CV) of log IC50 were calculated for each substance within each
laboratory (Supplement Tables 3 to 6) and across the laboratories
(Table 3).
Log IC50 showed best inter-laboratory consistency and good agree-
ment for both the WST-1 and BCA assay (Table 3, Supplement Tables 3
and 5). For 52 combinations (out of 60 for three laboratories and 20 sub-
stances) log IC50 values for WST-1 could be estimated numerically, en-
abling calculation of intra- and inter-laboratory CV. About two thirds
of the inter-laboratory CV values were lower than 5%; the maximum
value was 16%. For 7 substances an intra-laboratory CV greater than
10% was determined. All inter-laboratory CV values were lower than
10%. For all experiments conducted with lactose and MMA log IC50
values were estimated greater than the maximum applied concentra-
tion (except one replication of laboratory A). Similar results have been
observed for the BCA assay where the intra- and inter-laboratory CV
values were only in few cases between 10% and 20%. Thus, these results
were (at least) qualitatively reproducible.
Analysis of inter-laboratory correlation of log IC50 values reached
satisfactory levels of agreement (Spearman r N 0.9, Fig. 4). BCA assay
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ries was also good (CV b 20%) for LDH assay. Intra- and inter-
laboratory variability was high for intracellular IL-1α ELISA with intra-
and inter-laboratory CV values reachingup to 50% and 25%, respectively.
In general, agreement between the readings of laboratory A versus B
was higher (Spearman) for all endpoints than between laboratories A
versus C and B versus C.
3.5. Correlation of in-vitro (ex-vivo) IC50 with in-vivo inhalation LC50 and
oral LD50 values
The substances used in this projectwere selected to represent differ-
ent chemical classes andmodes of action for which acute inhalation and
oral lethality data are available (i.e. Sigma, RTECS, ChemIDplus Lite,
TOXNET, ECHA, NIOSH Pocket Guide to Chemical Hazards, and unpub-
lished BASF studies, Supplement Table 1). For some chemicals we
found only inhalation LC50 values from studies with exposure durations
different from 4 h. In these cases, the LC50 values were converted to 4-
hour LC50 values (see also material and method section). The in-vivo
data were then converted to molar concentrations, ranging from
0.01 μM for paraquat to 1.2 mM for acetone. Published oral rat LD50
values were also converted to molar-based doses which ranged from
222 μmol/kg for paraquat to 153mmol/kg for ethanol and (Supplement
Table 1). Thus, the most toxic substance via inhalation and oral uptake
was paraquat. The least toxic substances were acetone for inhalation
and ethanol for oral administration.
The results of theWST-1 assay were used for development two pre-
diction models (prediction of LC50 by IC50 and two-group classiﬁcation
model). TheWST-1 assaywas selected because (i) it provides toxicolog-
ically relevant mechanistic evidence for cell injury, and ii) delivered a
more complete data set as the LDH assay. Secondly wewanted to estab-
lish a model which has highest prospects for further validation. All end-
points were quite similar (high correlation) and the combination of two
assays provided no additional information.
For correlation analysis, IC50 values i.e. themedians of the laboratory
means obtained byWST-1 assay in rPCLS and/values of acute inhalation
(LC50) and oral lethality (LD50) in rats were used for linear regression.Fig. 2.Mean of log transformed IC50 [μM] values (log IC50) for all chemicals ordered by magnitu
(intIL-1α). Lab.: laboratory. For “N” values, minimum values have been entered.No in-vivo inhalation toxicity data were available for paracetamol (in-
halation), lactose (inhalation), and HCF (oral) (Supplement Table 1).
Medians [μM] of IC50 values of rPCLS correlated highly signiﬁcantly
with rat LC50 values [μM] from inhalation studies (Pearson correlation
coefﬁcient r = 0.87, p b 0.0001) and with rat LD50 values [μmol/kg]
from oral studies (Pearson correlation coefﬁcient r = 0.75, p =
0.0002) (Fig. 5).
3.6. Two-group classiﬁcation model
In the two-group classiﬁcation model, substances were divided into
two classes (toxic and non-toxic) based on their in-vivo inhalation tox-
icity. Substances with GHS categories 1, 2, and 3 were assigned to the
toxic class. Substances with GHS categories 4 and 5 were classiﬁed as
“non-toxic”. Subsequently, the results of the WST-1 assay were used
to determine thresholds. Each substance whose median was below
this threshold was classiﬁed as “toxic”, whereas substances with medi-
an values above the threshold were classiﬁed as “non-toxic. The good-
ness of prediction of the two-group classiﬁcation model was assessed
in terms of speciﬁcmeasures of the Cooper statistics, namely: sensitivity
and speciﬁcity.
Median log IC50 values of each substancewere used for classiﬁcation.
Since for lactose and MMA no effect could be determined up to a loga-
rithmic dose of 5.7 on a μM scale, the median of log IC50 values of
these two substances could not be expressed precisely. Therefore, we
assumed for lactose and MMA the highest applied concentration as
minimal possible IC50 value. To test robustness of the model even
lower values were assumed for both substances which ﬁnally resulted
only in small differences in classiﬁcation. For the two-group classiﬁca-
tion model, IC50 values were transformed to mg/L units, considering
the molecular weights of each substance. Thresholds of log IC50 for
two-group classiﬁcation were calculated to be 3.83 for laboratory A,
3.88 for laboratory B, and 3.91 for laboratory C. Classiﬁcation of the sub-
stances using the two-group classiﬁcationmodel is presented in Table 4
and Fig. 6. Sixteen out of 20 substances were classiﬁed correctly in all
laboratories, thereof six substances of the non-toxic class and ten of
the toxic class. Four substances, namely three non-toxic and one toxicde is shown for (A)WST-1 assay, (B) LDH assay, (C) BCA assay, and (D) intracellular IL-1α
Fig. 3. Extracellular IL-1α (extIL-1α) of rPCLS after 1 h exposure to increasing concentrations of indicated substances. Cytokine levels were determined by ELISA. Data are presented as
mean ± S.E.M. n = 3. *p b 0.05, **p b 0.01, and ***p b 0.001. Lab.: laboratory.
355A. Hess et al. / Toxicology in Vitro 32 (2016) 347–361in-vivo, were classiﬁed falsely in all laboratories. TDI was falsely classi-
ﬁed as non-toxic, whereas TMA, AHCP, and ZnO were classiﬁed falsely
as positive in all laboratories (Table 4, Fig. 6). Thus, only one substance
was false negative. Consequently, sensitivity was 91% and speciﬁcity
was 66% in all participating laboratories. Assuming lower values for lac-
tose and MMA changed the sensitivity of laboratory A to 82% and the
speciﬁcity of laboratory C to 78%.
All results were obtained in leave-one-out cross-validation which is
a model technique for evaluating how the results of a statistical analysis
will generalize to an independent data set. This gives the possibility to
estimate how accurately a predictive model will perform in practice
(Geisser and Seymour, 1993; Kohavi, 1995). Thus, the toxicity of each
substance per endpoint and laboratory combination was predicted by
a model trained on subsets of data of all other substances for the same
endpoint and laboratory combination without the subset data of the
same substance.
3.7. Prediction of the LC50 by IC50
The two-group classiﬁcationmodel used in this study is a simpliﬁca-
tion of the actual toxicity. When using only toxic versus non-toxic class,
the steepness of toxicity is not included, i.e. highly toxic (GHS category
1) and less toxic (GHS category 3) are all combined in the toxic class.
Therefore, we have also viewed on how highly toxic substances (e.g.
members of GHS category 1 such as TDI, IPDI, and paraquat) came out.
We used linear regression analysis to develop a prediction model
which allows predicting in-vivo toxicity based on observed in-vitro cy-
totoxicity. In order to obtain a prediction model allowing estimation of
LC50 by IC50, linear regression analysis was performed with values
from every laboratory. The log IC50 values of the WST-1 assay wereregarded here as predictors and the log-transformed LC50 values as re-
sponse. The obtained formula is given in the material and methods sec-
tion. The coefﬁcients were estimated by the least-square method as
β0 =−3.11 and β1 = 0.9252 for laboratory A, β0 =−3.12 and β1 =
0.9287 for laboratory B, andβ0=−2.53 andβ1=0.7993 for laboratory
C. Variances explained (i.e. the square of correlation coefﬁcient) by this
modelwere 63% for laboratory A, 63% for laboratory B, and 0.55% for lab-
oratory C.4. Discussion
4.1. Application of ACs to the different endpoint assays
At the beginning of this project, a standardized rPCLS protocol was
established and variances in assay performance were determined. The
basic protocol and technique for preparation of rat lung tissue sections
closely followed those published in previous reports (Held et al., 1999;
Ressmeyer et al., 2006). Initial sets of experiments using a ﬁrst selection
of six substances were focused on the deﬁnition of AC and subsequently
applied to the remaining substances. When applying the ACs to each
endpoint, WST-1, LDH, and BCA assays showed good validity, as the
ACs were met by more than 95%. More difﬁculties in meeting the ACs
were seen with the ELISA. The endpoint was highly sensitive to experi-
mental conditions (e.g. differences in technical equipment, see also
Materials and methods) beyond description in SOPs. Standardization
was therefore not entirely possible. Experiments that did not meet all
AC were not used for calculation of IC50 values but, instead, they were
repeated and the data used for subsequent determinations of IC50
values.
Fig. 4. Inter-laboratory correlation of mean log-transformed IC50 values [μM] obtained byWST-1 assay and BCA assay. The data of every laboratory was plotted against the data of every
other laboratory. Comparison was performed by non-parametric Spearman correlation. For illustration only result of linear regression is shown as line and 95% conﬁdence intervals are
shown as dashed lines. Lab.: laboratory.
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Two endpoint assayswere used for cytotoxicity: (i) determination of
cell death asmeasured by leakage of the cytosolic enzyme LDH into cul-
ture medium (Legrand et al., 1992), and (ii) loss of metabolic enzyme
activity assessed with the water-soluble dye WST-1 (Vistica et al.,
1991).
Initially we thought that comparison of several viability endpoints
could provide useful complementary data for (mechanistic) cytotoxici-
ty, avoiding misinterpretation of chemicals interfering with the assay
system. WST-1 assay provided the most complete and promising data
set. LDH assay also proved to be responsive, ranking the chemicals in
nearly the same order as theWST-1 assay but high substance concentra-
tions induced wash-out effects. Thus, changing the medium after 1 h of
incubation inﬂuences the outcome of the LDH assay. The wash-outeffects were observed at high concentrations of AcO2, ethanol, HCF,
OC, SDS, TDI, TMA, and TX-100. It was the main reason why these sub-
stances failed to be ﬁtted. The use of later time points for LDH is often
hampered by interferences of substances (e.g. AHCP, TMA) with the
LDH activity (Lauenstein et al., 2014). Although the LDH assay was per-
formedexactly the sameas theWST-1 assay, itwas actually not less pre-
dictive but less “practicable”. Manual analysis and ﬁtting of the big data
set was not feasible. Altogether, the LDH assay was as responsive – also
for 1 hour exposure – as the WST-1 assay but its further use was hin-
dered by the limited efﬁciency during automatic data analysis.
It is worthmentioning here that BCA assay was standardized for de-
termination of total protein content, but also reﬂected substance-
induced cytotoxicity. The BCA assay was less responsive, as shown by
the fact that WST-1 assay indicated cytotoxicity for some substances
at lower concentrations already.
Fig. 5. Correlation of ex-vivo IC50 (WST-1 assay)with in-vivo inhalation LC50 (A, B) and oral LD50 values (C, D). In-vivo data were taken from online databases (Sigma, RTECS, ChemIDplus
Lite, TOXNET, ECHA, and NIOSH Pocket Guide to Chemical Hazards) and converted to molar amounts (details are given in Supplement Table 1). IC50 values obtained by WST-1 assay in
rPCLS and LC50/LD50 values of acute inhalation and oral lethality in rats were used for linear regression analysis. A) Correlation shown for all substances except lactose, paracetamol
(unknown LC50 values), MMA (no deﬁned IC50 value), ZnO, TMA, AHCP, SDS (no deﬁned LC50 values). B) Correlation shown for all substances except lactose, paracetamol (unknown
LC50 values). For MMA, ZnO, TMA, AHCP, and SDS minimum values were used. C) Correlation shown for all substances except lactose, MMA (no deﬁned IC50 values), and HCF
(unknown LD50 value). D) Correlation shown for all substances except HCF (unknown LD50 value). For MMA and lactose minimum values were used. 95% conﬁdence interval is shown
as gray dashed line. 95% prediction interval is shown as black dashed line. Symbol colors refer to GHS classes as follows: 1 = red, 2 = orange, 3 = blue, 4 = light green, 5 = dark
green.
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assays (LDH and WST-1) for cytotoxicity (with or without BCA assay)
was not more sensitive and reliable than the WST-1 assay alone. The
combination of the two assays did not provide additional complementa-
ry data. All substances that reduced the metabolic activity of the tissue
also induced an increase in LDH activity in supernatant. Using the twen-
ty described substanceswe foundno casewhere itwas contrary, e.g. de-
crease of tissue activity without detectable LDH leakage (e.g. due to
substance interference).
4.3. Can IL-1α be used as biomarker for inﬂammation?
For inﬂammation we used only one endpoint. Substance-induced
pro-inﬂammatory responses were assessed by quantiﬁcation of IL-1α.
This is a protein of the interleukin-1 family that has strong pro-
inﬂammatory effects in the body, promoting the development of sepsis
and fever (Dinarello, 2009; Frank et al., 2008; Sims and Smith, 2010). In
lung tissue, IL-1α is producedmainly bymonocytic cells such as activat-
ed macrophages, but also by epithelial and endothelial cells (Suwara
et al., 2014). IL-1α has been reported to be an indicator of inﬂammationin lung tissue, e.g. due to exposure to LPS, adjuvants, or chemicals (Cao
et al., 2011;Henjakovic et al., 2008; Xing et al., 1994). In our study, IL-1α
responsiveness of rPCLS to LPS and substance treatments was quantita-
tively extremely variable within all laboratories. In rPCLS IL-1α peaks
intracellularly at 24 h after permanent exposure to LPS (Henjakovic
et al., 2008). Interestingly, some substances such as Ac2O and AHCP,
known to induce respiratory inﬂammation accompanied by cellular in-
ﬁltration and edema, signiﬁcantly increased extracellular IL-1α levels in
rPCLS (Fig. 3). On the other hand, substances such as lactose and MMA
showed no effect on IL-1α levels. Although IL-1α could not be used to
derive IC50, these results suggest that IL-1α could be a marker for the
prediction of substance induced inﬂammatory effects. Further efforts
are needed to assess the usefulness of this information, and to establish
it as valid and reliable endpoint as the inter-laboratory concordancewas
insufﬁcient.
4.4. Intra- and inter-laboratory variabilities
The results from each laboratory were evaluated concerning intra-
and inter-laboratory variability. Variability within and between
Table 4
Classiﬁcation of substances using the binary prediction model. The number of each sub-
stance refers to known order in inhalation toxicity (see also Table 1). Lab.: laboratory;
tox: toxic; non: non-toxic.
# Substance In vivo Ex vivo
Lab. A Lab. B Lab. C
1 Paraquat Tox Tox Tox Tox
2 IPDI Tox Tox Tox Tox
3 TX-100 Tox Tox Tox Tox
4 TDI Tox Non Non Non
5 AHCP Non Tox Tox Tox
6 GA Tox Tox Tox Tox
7 SDS Tox Tox Tox Tox
8 OC Tox Tox Tox Tox
9 HCF Tox Tox Tox Tox
10 FA Tox Tox Tox Tox
11 TMA Non Tox Tox Tox
12 Ac2O Tox Tox Tox Tox
13 Aniline Tox Tox Tox Tox
14 ZnO Non Tox Tox Tox
15 DMF Non Non Non Non
16 MMA Non Non Non Non
17 Ethanol Non Non Non Non
18 Acetone Non Non Non Non
19 Lactose Non Non Non Non
20 Paracetamol Non Non Non Non
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variability, and strong agreementwere found forWST-1 andBCA assays.
Both assays were comparably robust. Results for LDH assay were found
to be moderately matching, whereas intra- and inter-laboratory vari-
ability was high for IL-1α determination by ELISA. In summary, WST-1
assay seems to be best suited for analysis of cytotoxicity in rPCLS. The
assay was transferable between the laboratories and provided relevant
and reproducible results. The same was true for BCA assay used for de-
termination of total protein content. The transferability of the ELISA
based quantiﬁcation of IL-1αwas only limited, and results were less re-
producible and very sensitive to laboratory speciﬁc conditions. In gener-
al, with a sample size of three biological replicates, the results have to be
interpreted very carefully and need further validation.
Ranking of substances in the ex-vivo assay correlated well with un-
derlying toxicological mechanisms. TX-100 is one of the most toxic
compounds in-vivo and was ranked as most toxic in the ex-vivo
model. Among the most toxic substances was also SDS, which is used
as detergent, too. Both chemicals are known to disrupt cell membranes.
SDS denatures proteins at higher concentrations (Chaturvedi andFig. 6. Classiﬁcation of substances using the binary prediction model. Means of log IC50 as
obtained byWST-1 assay were converted to mg/L and ranked according to GHS category.
GHS categories 1, 2, and 3were sorted in toxic class. GHS categories 4 and 5were sorted as
non-toxic class. Red line indicates the ex-vivo threshold value. Small numbers above the
symbols refer to the GHS class of each substance. Lab.: laboratory.Kumar, 2011). Other chemicals such as isocyanates are known to attack
proteins which lead to disturbance of cellular processes in e.g. metabo-
lism, proteolysis, proliferation and protein synthesis. Substances such as
Ac2O change their chemical structure. In aqueousmedia, Ac2O hydroly-
ses to acetic acid within few minutes. In our study the effects of Ac2O
and acetic acid cannot be distinguished. In-vivo toxic threshold concen-
trations for Ac2O were found to be lower (about half) than for acetic
acid. This is suggesting initial toxic effect by the anhydride before it hy-
drolyzed to acetic acid (OECD SIDS, 1997). Moreover, some chemicals
were able to change the pH of the medium. They were not neutralized
before they were applied to the test system in order to mimic real-life
exposure. As test substances were incubated with rPCLS under sub-
merged conditions, chemicals with limited water solubility such as
TMA were initially dissolved in appropriate solvents. These solvents
showed no effects at the ﬁnal concentrations used.
4.5. The two prediction models
For comparison with in-vivo data we developed two prediction
models. The ﬁrst prediction model was a two-group classiﬁcation
model where substances were divided into two classes based on their
in-vivo acute inhalation toxicity. Substances with GHS categories 1, 2,
and 3 were assigned to the toxic class and substances with GHS catego-
ries 4 and 5 to the non-toxic class. With this approach, 16 out of 20 test
substances were classiﬁed correctly in all laboratories (Fig. 6). The rea-
son why TDI and ZnO were falsely classiﬁed is most probably the
same as that explaining the outliers in the second predictionmodel pro-
posed in the next section below. A sensitivity of 91% was found for all
laboratories, whereas the speciﬁcity was calculated at 66% for all
laboratories.
The secondpredictionmodelwas based on linear regression analysis
of ex-vivo and in-vivo data. IC50 values obtained by WST-1 assay in
rPCLS showed signiﬁcant correlation with LC50 of in-vivo inhalation
rats. The results can potentially be used to predict starting concentra-
tions of acute inhalation toxicity studies. Signiﬁcant correlation was
also observed with LD50 values of oral studies in rats. Nevertheless,
some outliers were obvious: (Akaike, 1998) Although paraquat is the
substance with the lowest LC50 among the selected substances, it is
ranked only on seventh position in the ex-vivo model (WST-1 assay)
and was about 30 times less toxic than the most toxic substance ex-
vivo TX-100. The lung is the primary target organ of paraquat. However,
the primary underlying mechanism of paraquat is oxidative damage,
which – and this is remarkable – leads to delayed toxic damage of
lung tissue via pulmonary ﬁbrosis. In the end, this condition is the
usual cause of death after exposure to paraquat and which most com-
monly occurs 7–14 days after acute exposure (EPA Handbook, 2006).
It shows that substances with long term effects such as paraquat can
be tested only to a limited extent in acute models. (Archer et al.,
1997) ZnO is less toxic in in-vivo studies (GHS category 5). In the
rPCLSmodel, it ranked among theﬁvemost toxic substances. The differ-
ence is that ZnOwas dissolved in acetic acid before application to rPCLS,
whereas in-vivo it is inhaled in the undissolved form as dust (Klimisch
et al., 1997). Toxicity of dissolved ZnO has been reported to be due to
zinc ion concentrations leading to mitochondrial dysfunction, caspase
activation, and apoptosis (Kao et al., 2012). Therefore, it can also not
be compared to Sauer et al., 2014 where ZnO was applied as
nanomaterial for 24 h. (Balls and Fentem, 1999) The diisocyanates
IPDI and TDI are highly toxic in-vivo (GHS category 1) and ranked
among the ﬁve most potent substances used in this study, but
showed only minor cytotoxic effects ex-vivo. TDI in particular reacts
quickly with water and its half-life time in water is only a few mi-
nutes (Collins, 2002). IPDI is more stable and remains in aqueous so-
lutions for some hours (OECD SIDS, 2006). This might be the reason
why the ex-vivo IC50 value of IPDI is about 30 times lower than that
of TDI, whereas in-vivo both compounds differ only by a factor of
six. It shows that substances being unstable in solution such as
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exposure conditions.
Both prediction models were based on the use of the median IC50
values. In general, models using concentrations different from IC50
may be of interest in future. Benchmark Dose (BMD) for example can
also rank potencies of substances based on in-vitro dose–response
curves even when no IC50 can be calculated (Louisse et al., 2010).
With this approach doses for low effect levels such as a 5–10% change
from baseline can be estimated and subsequently converted into pre-
dicted in-vivo doses. Although it was not applied in this study it could
be an interesting approach in future.4.6. How does the results compare to other in-vitro models?
In the following discussion our results are comparedwith other pub-
lished in-vitro models. A recently published study (Sauer et al., 2013)
investigated responses of the two commercially available 3D models,
MucilAir™, and EpiAirway™, and of two monolayer cell lines, human
A549 epithelial cells and 3T3 mouse embryonic ﬁbroblasts, to the
same chemicals as assessed in the present study. IC50 values using the
MTT and WST-1 assays have been reported. We used these published
IC50 values for direct correlation to in-vivo lethality data by linear re-
gression analysis. The IC50 values of each model correlated signiﬁcantly
with oral LD50 and inhalation LC50 values (Supplement Fig. 1). Remark-
able is the dynamic range spreading the data, which for the same
chemicalswas less pronounced for single-cell cultures (4 orders ofmag-
nitude for A549and 3T3) than for in-vivo toxicity data (6 orders of mag-
nitude). Among these models, rPCLS was the ﬁrst model used for
prevalidation. In comparison with the other models, rPCLS correlated
best with in-vivo data (Pearson r = 0.87). But also A549, MucilAir™,
and EpiAirway™ showed good correlation with in-vivo (Pearson r
0.85, 0.84 and 0.83, respectively) (Supplement Fig. 1). Only 3T3 cells
did not correlate well (Pearson r = 0.71). Interestingly, all models
showed similar outlier pattern, as discussed already above for the re-
sults of the present study.
The question needs to be discussed whether for endpoints such as
cytotoxicity single cell lines can be taken. The results of the study
show that among the tested cell lines only alveolar epithelial cells
such as A549 correlated well with in-vivo whereas the ﬁbroblast
cell line 3T3 did not. Lauenstein et al. (2014) showed that cells in
human lung tissue behave more like monocyte-derived cells regard-
ing their resistance to chemicals than skin-derived epithelial cells.
This supports the theory that different cell populations have differ-
ent responsiveness to chemicals. In the lung more than 45 different
cell types can be found. Epithelial cells, nerve ﬁbers, monocytes/
macrophages, dendritic cells are in the ﬁrst line of defense. All of
them may respond differently to the same substance, some cell
types even possess receptors that provide a chemical sensation
(Guilliams et al., 2013). In the context of likely exposed cells the ad-
vantage of an ex-vivo tissue culture model is its multicellular micro-
anatomy which is very attractive for a ﬁrst assessment of acute local
respiratory toxicity.
Moreover, we want to develop a model in future that is not mere-
ly based on cell injury but also provide early biomarkers for respira-
tory inﬂammation and chronic diseases, such as sensitization,
proliferation, and ﬁbrosis. The use of cell cultures is limited as pub-
lished by Lauenstein et al. (2014). Here it was shown that bio-
markers developed in cell culture were not proven to be predictive
and reliable in human lung tissue. Switalla et al. (2010) showed
that biomarkers in human lung tissue ex-vivo correlated very well
with in-vivo response of probands. Nevertheless, in face of the differ-
ent adverse effects after inhalation of toxicants it seems to be unlike-
ly to develop a single approach – be it cell lines or tissue models –
predicting the entire diversity of biological responses of the respira-
tory tract in acute toxicity studies.4.7. Translation from in-vitro to in-vivo
The comparison of animal toxicity data with in-vitro/ex-vivo data
remains critical due to the following issues: i) Differences can occur,
for example, in the site of action, which can be different from the site
of exposure. ii) Only a small number of substances was used in our
study. Retrospective analysis of more than 300 chemicals tested accord-
ing to the guidance document for oral toxicity has shown that a larger
number of test chemicals provides different outcomes than the initial
studies using less substances (Schrage et al., 2011). iii) Biotransforma-
tion in rPCLS remains questionable. Although, the lungs have been re-
ported to have considerable capacity for metabolism (De Kanter et al.,
2004), the rPCLSmodel has to be characterized using substances requir-
ing biotransformation. Among the so far twenty tested substances
only paracetamol requires biotransformation. Its metabolite is
known to cause liver toxicity. Paracetamol showed weak toxicity in
rPCLS suggesting somewhat biotransformation in rPCLS. iv) Expo-
sure was done under submersed conditions. Whether or not rPCLS
can be used to test, for example, nanomaterials, pesticides, metal
compounds, and other industrial substances could not be addressed
in this study. In particular, the use of rPCLS for the testing of
chemicals quickly reacting with aqueous solutions might be limited
(Landsiedel et al., 2010; Monopoli et al., 2011; Sauer et al., 2014).
v) The model was set up as an acute exposure model. Long-term ef-
fects leading to development of ﬁbrosis cannot be studied (Bonﬁeld
et al., 1995; Gwyer Findlay and Hussell, 2012; Yankaskas et al.,
2004). Nevertheless, within this pre-validation study the respiratory
toxicity data obtained for the selected substances reﬂected the in-
vivo situation very closely. Issues that need to be reﬂected and one
has to be aware of have been discussed above.4.8. Conclusions and perspective
In conclusion, rPCLS as a test system for cytotoxicity can be part of a
test battery of different in-vitro or in-vivo models to reﬂect the various
processes associated with inhalation toxicity (Sauer et al., 2013).
Whether or not this alternative can eventually be used to reduce or
even replace in-vivo studies can only be answered by analyzing a larger
set of new reference chemicals different from the set used in our study.
However, according to the internationally recognized principle of a
modular approach to validation (Hartung et al., 2004; OECD GD 34,
2005), the current study may be accepted already as a sufﬁcient proof
of intra- and interlaboratory reproducibility, and reproducibility over
time. Thus, a new, independent data set might not necessarily have
to be tested again in three laboratories. The main goal of such a spe-
cial study would be a robust veriﬁcation of the prediction models de-
veloped here post hoc with the data obtained from twenty reference
chemicals in three laboratories. Since results of statistical cross-
validation applied here to the training data set of twenty chemicals
suggest robustness of the prediction models also when applied to
new data, the current study offers a particularly good basis for a spe-
cial follow-up study focused only on veriﬁcation of the prediction
models as one important part of the validation module “relevance”.
A pre-submission of this approach to EURL/ECVAM and a check by
the independent Boards of EURL/ECVAM (PARERE, ESTAC and
ESAC) could aid deciding about the design of follow-up Validation
Study (module).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tiv.2016.01.006.Transparency document
The Transparency document associated with this article can be
found, in the online version.
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